Abstract: Compounds of the formula where the variables are as defined in the specification inhibit the NS3 protease of flavivirus such as hepatitis C virus (HCV). The compounds comprise a novel linkage between a heterocyclic P2 unit and those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.
Abstract: The present invention relates to new agents and methods useful for preventing, treating and diagnosing diseases such as cancer. For example, the invention relates to prodrug agents useful for targeting and delivering cytotoxic drugs to cancerous cells.
Abstract: A method of enzymatically producing a protein hydrolysate from a protein substrate is described, wherein a proline-specific endoprotease or a composition containing a proline-specific endoprotease and optionally a subtilisin or a metallo endoprotease, and other enzymes such as carboxypeptidases, is used to produce a protein hydrolysate enriched in peptide fragments having a carboxy terminal proline residue. Such protein hydrolysates may be used as such or to reduce bitterness in foods nutritionally supplemented by protein hydrolysates, as well as to produce hydrolysate containing foodstuffs having low antigenicity.
Type:
Grant
Filed:
December 6, 2001
Date of Patent:
October 27, 2009
Assignee:
DSM IP Assets B.V.
Inventors:
Luppo Edens, Robertus Antonius Mijndert Van Der Hoeven, Veronique Delest
Abstract: Peptide and peptides that may be covalently linked to a lipid and methods of using such peptides and lipopeptides to prevent or treat disease are disclosed herein.
Abstract: Peptide factors isolated from skin following exposure to chemical or thermal injury and treatment with iodine preparations are capable of reducing or ameliorating the extent of injury when administered to other animals. Specific peptides, including fragments of histone H2A and fibrinopeptide A, and preferred derivatives of these peptides are disclosed. Pharmaceutical compositions and methods of using these peptides are also disclosed. The extracts, peptides and pharmaceutical compositions according to the invention are useful for the prevention and treatment of inflammatory conditions and exposure to noxious stimuli.
Type:
Grant
Filed:
May 18, 2007
Date of Patent:
October 20, 2009
Assignee:
Yissum Research Development Company of the Hebrew University of Jerusalem
Abstract: Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally, classes of analogs, in which the various substitutions comprise the non-standard residues norleucine and/or norvaline, are disclosed.
Type:
Grant
Filed:
June 16, 2006
Date of Patent:
October 20, 2009
Assignee:
MannKind Corporation
Inventors:
Liping Liu, Adrian Bot, David C. Diamond
Abstract: Administering an effective dose of a tTGase inhibitor to a Celiac or dermatitis herpetiformis patient reduces the toxic effects of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.
Type:
Grant
Filed:
May 14, 2003
Date of Patent:
October 20, 2009
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Abstract: The present disclosure relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
Type:
Grant
Filed:
July 6, 2006
Date of Patent:
October 13, 2009
Assignee:
Bristol-Myers Squibb Company
Inventors:
Piyasena Hewawasam, Min Ding, Li-Qiang Sun, Paul Michael Scola
Abstract: This invention provides cross-linked glycopeptides—cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds.
Type:
Grant
Filed:
August 24, 2007
Date of Patent:
October 13, 2009
Assignee:
Theravance, Inc.
Inventors:
Paul R. Fatheree, Martin S. Linsell, Daniel Marquess, S. Derek Turner
Abstract: Pharmaceutical batch(es) or pharmaceutical formulation(s) comprising bivalirudin as the active ingredient, and a method of preparing the pharmaceutical batch(es) or pharmaceutical formulation(s). The pharmaceutical batch(es) or pharmaceutical formulation(s) may have a maximum impurity level of Asp9-bivalirudin that does not exceed about 0.6%. Also, the pharmaceutical batch(es) or pharmaceutical formulation(s) may have a reconstitution time that does not exceed about 42 seconds. The method of preparing the pharmaceutical batch(es) or pharmaceutical formulation(s) may comprise dissolving bivalirudin in a solvent to form a first solution, efficiently mixing a pH-adjusting solution with the first solution to form a second solution in which the pH-adjusting solution may comprise a pH-adjusting solution solvent, and removing the solvent and the pH-adjusting solution solvent from the second solution.
Abstract: Disclosed are processes for liquefaction and saccharification of polysacharide containing biomasses having high dry matter content (>20%) and preferably possessing large average particle size. The polysaccharide containing biomasses are subject to enzymatic hydrolysis in a mixer that utilizes “free fall” mixing. “Free fall” mixing provides mechanical degradation of the biomass during hydrolysis and, in the case of lignocellulosic biomass, promotes movement of cellulase enzymes along cellulose chains, which improves enzymatic hydrolysis at high dry matter.
Type:
Grant
Filed:
April 15, 2008
Date of Patent:
October 6, 2009
Assignee:
Inbicon A/S
Inventors:
Claus Felby, Jan Larsen, Henning Jørgensen, Jakob Vibe-Pedersen
Abstract: The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide agonists, containing one or more native or non-native glycosylation sites. The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide agonists, containing one or more native or non-native glycosylation sites, as well as erythropoietin and darbepoetin alfa, each of which are linked to a penetrating peptide that facilitates translocation of a substance across a biological barrier as well as pharmaceutical compositions, including oral formulations, of the same.
Type:
Grant
Filed:
February 8, 2006
Date of Patent:
October 6, 2009
Assignee:
Alios BioPharma, Inc.
Inventors:
Lawrence M. Blatt, Scott D. Seiwert, Jin Hong
Abstract: The present invention discloses novel peptide compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
Inventors:
Anil Saksena, Viyyoor M. Girijavallabhan, Stephane L. Bogen, Raymond G. Lovey, Edwin Jao, Frank Bennett, Jinping L. McCormick, Haiyan Wang, Russell E. Pike, Yi-Tsung Liu, Tin-Yau Chan, Zhaoning Zhu, Ashok Arasappan, Kevin X. Chen, Srikanth Venkatraman, Tejal Parekh, Patrick A. Pinto, Bama Santhanam, F. George Njoroge, Ashit K. Ganguly, Henry A. Vaccaro, Scott Jeffrey Kemp, Odile Esther Levy, Marguerita Lim-Wilby, Susan Y. Tamura
Abstract: Novel biologically active compounds of the general formula (I) in which one of X and X? represents a polymer, and the other represents a hydrogen atom; each Q independently represents a linking group; W represents an electron-withdrawing moiety or a moiety preparable by reduction of an electron-withdrawing moiety; or, if X? represents a polymer, X-Q-W- together may represent an electron withdrawing group; and in addition, if X represents a polymer, X? and electron withdrawing group W together with the interjacent atoms may form a ring; each of Z1 and Z2 independently represents a group derived from a biological molecule, each of which is linked to A and B via a nucleophilic moiety; or Z1 and Z2 together represent a single group derived from a biological molecule which is linked to A and B via two nucleophilic moieties; A is a C1-5 alkylene or alkenylene chain; and B is a bond or a C1-4 alkylene or alkenylene chain; are formed by conjugating a suitable polymer to a suitable biologically active molecule via nuc
Type:
Grant
Filed:
July 12, 2004
Date of Patent:
September 29, 2009
Assignee:
Polytherics Limited
Inventors:
Stephen James Brocchini, Antony Robert Godwin, Elisa Pedone, Jin-Won Choi, Sunil Shaunak
Abstract: Provided are methods and compositions for maintaining the viability of photoreceptor cells following retinal detachment. The viability of photoreceptor cells can be preserved by administering a neuroprotective agent, for example, a substance capable of suppressing endogenous calcineurin or constitutively active calcineurin, inhibiting cleavage of calcineurin to constitutively active calcineurin, and/or directly or indirectly antagonizing calcineurin or constitutively active calcineurin (and combinations thereof), to a mammal having an eye with retinal detachment. The neuroprotective agent maintains the viability of the photoreceptor cells until such time that the retina becomes reattached to the underlying retinal pigment epithelium and choroid. The treatment minimizes the loss of vision, which otherwise may occur as a result of retinal detachment.
Abstract: A method for removing leukocytes, whereby leukocytes can be removed at a higher level of performance in a short filtration time without clogging. A method comprising passing a leukocyte-containing liquid through a filter for removing leukocytes made of a nonwoven fabric having an average fiber diameter of from 0.3 to 3.0 ?m, and thus removing the leukocytes from the leukocyte-containing liquid, to give a leukocyte-free liquid, characterized by using a nonwoven fabric having a formation index (y) of 50 or less corresponding to a thickness of 0.3 mm; use of a leukocyte removal filter therefore; and the leukocyte removal filter.
Abstract: The instant invention provides for compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.
Type:
Grant
Filed:
February 10, 2006
Date of Patent:
September 15, 2009
Assignee:
Merck & Co., Inc.
Inventors:
Nicholas D. P. Cosford, Mark E. Layton, Jun Liang, Craig W. Lindsley, Philip E. Sanderson, Zhijian Zhao